In compliance with Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (LODR Regulations), we wish to inform you that the Board of Directors in their meeting held today, i.e. May 12, 2017 , approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited (' the Transferor Company'), a wholly owned subsidiary of Dr. Lal PathLabs Ltd. ('Company') with the Company with effect from 1st April, 2017 ('Appointed Date'), pursuant to sections 230-232 of the Companies Act, 2013. The scheme is conditional upon and subject, inter alia, to sanction of the same by the Hon'ble National Company Law Tribunal ('NCLT'). As the Transferor Company is a wholly owned subsidiary of the Company, hence the Company is neither required to comply with the requirements laid under Circular No. CFD/DIL3/CIR/2017/21 dated 10th March, 2017 nor required to obtain observation letter or no objection letter from the stock exchange before filing the scheme with any Tribunal as contemplated in Circular No. CFD/DIL3/CIR/2017/26 dated 23rd March, 2017. Enclosed as Annexure A is the information pursuant to Regulation 30 of the LODR Regulations read with Circular no. CIR/CFD/ CMD/4/2015 dated 9th September, 2015. Please find enclosed herewith the draft Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company with effect from April 1, 2017 ('Appointed Date') for your information. The scheme is conditional upon and subject, inter alia, to sanction of the same by the Hon'ble National Company Law Tribunal ('NCLT'). (As Per BSE Announcement Dated on 29.11.2017) We wish to inform you that Hon'ble National Company Law Tribunal ('NCLT'), New Delhi Bench-III has sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also. (As Per BSE Announcement Dated on 26.10.2018) In furtherance to our letter dated October 26, 201 8, we wish to inform you that Hon''ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench has sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company. (As Per BSE Announcement Dated on 14.12.2018) This is in furtherance to our letter dated December 14, 2018, wherein we informed that Hon'ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench, sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company. Please take note that consequent upon filing of ROC intimation on January 1, 2019, the Scheme has become effective. Accordingly January 1, 2019 becomes the effective date for the said Scheme of Amalgamation. Kindly take the same on record. (As Per BSE Announcement Dated On 02/01/2019)